Stay updated on CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial
Sign up to get notified when there's something new on the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page.

Latest updates to the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedAdded a Locations section listing new sites in Arizona, California, Connecticut, Florida, Maryland, Nebraska, New York, Ohio, Pennsylvania, and Tennessee. Removed the individual state location sections and the HHS Vulnerability Disclosure link; updated the revision from v3.3.2 to v3.3.3.SummaryDifference0.9%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check39 days agoChange DetectedA new revision label v3.3.1 was added and the previous v3.2.0 label was removed.SummaryDifference0.0%

- Check47 days agoChange DetectedThe page's funding notice about government operations has been removed; the study details, eligibility criteria, and locations remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check61 days agoChange DetectedNo significant changes to core study information (design, eligibility criteria, endpoints, or results) are evident between the screenshots; the differences appear limited to minor UI/formatting updates. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check89 days agoChange DetectedCore content updated with a government funding notice and updated operating-status guidance; version updated from v3.1.0 to v3.2.0.SummaryDifference3%

Stay in the know with updates to CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page.